New Delhi, Wednesday, March 25, 2026 – In a significant medical research breakthrough, preliminary results from Phase II clinical trials of a novel tuberculosis (TB) vaccine, conducted in multiple sites across India, show promising efficacy and safety. The vaccine, tentatively named 'ImmuTB', is being developed by a consortium of Indian and international researchers, with funding from the Department of Biotechnology (DBT), Government of India. This offers a beacon of hope in the ongoing fight against TB, which remains a major public health challenge in India

India bears a disproportionately high burden of TB, accounting for approximately 26% of the global TB cases, according to the World Health Organization (WHO). The current BCG vaccine, while effective in preventing severe forms of TB in children, offers limited protection to adults, who are the primary transmitters of the disease. This new vaccine aims to address this critical gap.

ImmuTB: A Potential Game-Changer in TB Prevention

The Phase II trials involved over 3,000 adult participants across various Indian states, including Maharashtra, Tamil Nadu, and Delhi. Participants were randomly assigned to receive either the ImmuTB vaccine or a placebo. Initial data indicates that ImmuTB demonstrated a significant reduction in the incidence of active TB disease among vaccinated individuals compared to the placebo group. The data is still being analysed, but scientists are very optimistic.

“These early results are incredibly encouraging,” said Dr. Priya Sharma, lead investigator of the ImmuTB trial at the All India Institute of Medical Sciences (AIIMS), New Delhi. “If confirmed in larger Phase III trials, ImmuTB could represent a major advancement in our efforts to control and ultimately eliminate TB in India.” Dr. Sharma told News Reporter Live that the next steps involve a larger, multi-year study to confirm these findings.

Addressing the Urgent Need for Better TB Vaccines

The development of new and more effective TB vaccines is a global priority, and the Indian government has been actively supporting research and development efforts in this area. The National Tuberculosis Elimination Programme (NTEP) has set ambitious goals for reducing TB incidence and mortality in India, and new tools like ImmuTB are crucial for achieving these targets. Latest Health News highlights the government's commitment to eradicating TB.

Speaking to News Reporter Live, Dr. Rajesh Kumar, a senior scientist at the Indian Council of Medical Research (ICMR), emphasized the importance of continued investment in TB research. “TB is a complex disease, and we need a multi-pronged approach to tackle it effectively. This includes not only developing new vaccines and drugs but also improving diagnostics and strengthening healthcare systems,” reportersays. He further added that collaboration between public and private sectors is crucial for accelerating the development and deployment of new TB interventions.

What's Next for the ImmuTB Vaccine?

The research team is now preparing to initiate Phase III clinical trials, which will involve a larger and more diverse population. These trials will further assess the vaccine's efficacy and safety, as well as its impact on TB transmission. The Phase III trials are expected to begin in early 2027, with results anticipated in 2030. If successful, ImmuTB could be licensed for use in India and other high-burden countries.

In the meantime, health officials urge the public to continue practicing preventive measures, such as maintaining good hygiene, ensuring proper ventilation in homes and workplaces, and seeking early diagnosis and treatment for TB symptoms. Free TB treatment is available under the Revised National TB Control Programme (RNTCP). Furthermore, individuals can explore Health Insurance & Financial Aid options to mitigate potential financial burdens associated with prolonged treatment.

As of today, the medical community celebrates this medical research breakthrough, with the hopes that ImmuTB will contribute significantly to finally controlling TB in India.

Explore More on News Reporter Live

Frequently Asked Questions

What are the early symptoms of Tuberculosis (TB)?

The primary symptoms of TB include a persistent cough lasting three or more weeks, coughing up blood or sputum, chest pain, weakness or fatigue, weight loss, loss of appetite, chills, fever, and night sweats. If you experience these symptoms, it's crucial to seek medical evaluation and testing promptly.

How can I protect myself and my family from TB?

Protect yourself by ensuring proper ventilation in your home and workplace, practicing good hygiene (covering your mouth and nose when coughing or sneezing), maintaining a healthy lifestyle to boost your immune system, and getting tested if you have been in close contact with someone with active TB. Early detection and treatment are key to preventing the spread of TB.

What is the Indian government doing to eliminate TB?

The Indian government is actively working to eliminate TB through the National Tuberculosis Elimination Programme (NTEP). This program provides free diagnosis and treatment for TB, implements active case finding, promotes awareness about TB prevention and control, and supports research and development of new TB interventions, including vaccines and drugs.